Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
August 6, 2025
Earnings Call Speaker Segments
Jost Reinhard
executiveGood afternoon, everyone, and good morning as well. Thank you for joining our conference call, where we'll be discussing the second quarter results for 2025. Our release came out at the end of last week, so you've already had a chance to see it. Today, Bill and Wolfgang will keep the prepared remarks centered on the business drivers and market dynamics that stand behind the figures, along with a few additional clarifying comments regarding litigation. After that, they'll be joined by the presidents of our three divisions for the Q&A. Before we start, please take note of the cautionary language contained in our safe harbor statement. With that said, Bill, over to you.
William Anderson
executiveThanks, Jost, and hello everyone — appreciate you being on the call. As you're aware, last week we put out a thorough update covering how '25 is performing and what we expect, along with provisions related to litigation. Those subjects are surely on people's minds, and we're glad to take them up during the Q&A. To keep from going over the same ground, though, my comments will center mostly on conditions within our businesses and the broader picture for Bayer. So — good, the first chart is up. Let's begin with the figures. As usual, when we discuss sales growth, it's on a currency- and portfolio-adjusted basis. Groupwide, sales were flat across the first half of the year. Core EPS came in at EUR 3.72. Free cash flow stands at minus EUR 1.4 billion, and we remain on track to hit our initial 2025 outlook. Within Crop Science, Q2 sales grew, mainly on the strength of our Corn business, taking half 1 sales to minus 1%. Our margin sits at 26%, unchanged versus a year earlier even with sales headwinds stemming from losing both dicamba and Movento because of regulatory events. Consumer Health is up 1% for the year. Growth stayed muted given soft market conditions in key regions and an allergy season that came in weaker than expected.
William Anderson
executiveLooking at the rest of '25, we anticipate that softer market conditions will stick around, especially in North America, though we're beginning to see a healthier growth contribution coming from our top brand and country intersections, which we refer to as power couples. That's an encouraging early signal that the investment and portfolio strategy we've put in place is paying off. Margin stands at 23%, somewhat ahead of where we were last year at this stage. Pharmaceuticals keeps growing. At the half 1 mark we're at 2%, driven by sustained growth behind Nubeqa and Kerendia, which together rose 65% year-over-year. Our Pharma margin is at 25%. Turning to the wider industry, we're continuing to watch ongoing developments on the geopolitical front. Our '25 Pharma outlook incorporates what we know about that impact. So given our year-to-date performance in Pharma, we are raising 2025 currency adjusted guidance for the group on both sales and earnings. Now, as we look forward, we're entering an important second half of '25, one that will be defined by further progress across all strategic priorities, our ongoing launches, and the geopolitical and currency crosswinds we'll need to navigate. Let me now turn to our priorities and highlight a few things. First, in addition to the operational success of our Pharma business, we keep seeing news flow around our pipeline and launch assets.
William Anderson
executiveBeyonttra became available in Germany on April 1, and we are moving quickly to expand it throughout Europe, with early-month signals looking promising. Beyond that, we have secured meaningful clearances for several other important medicines and pipeline assets, including significant label expansions for Eylea, Kerendia and Nubeqa. Regarding elinzanetant, now marketed under the name Lynkuet, the FDA has pushed out its review schedule, and we anticipate a conclusion within the coming 90 days. In the U.K. and Canada, our first approvals have come through from the regulators. Our Crop Science group is progressing on its initiative to boost profitability. We have agreed on the core elements of a joint declaration with worker representatives, and we can now start simplifying production and operations. We have also hit key milestones for our Crop Protection portfolio. Dicamba has received a proposed approval from the EPA, and icafolin — our blockbuster herbicide molecule — was recently filed for approval in the U.S., Canada, Brazil and the EU. Now I will cover where we stand in combating litigation. Last week, we announced settlements and substantial provisioning aimed at curbing our exposure to the litigation industry. Such decisions form part of our multipronged approach to meaningfully rein in litigation by the end of 2026, which we reaffirm today.
William Anderson
executiveTo put it plainly, each choice we make is aimed at putting the company in position to get beyond our litigation was. So here is a summary of where things stand right now. Back in June, the U.S. Supreme Court asked the Solicitor General for input on the glyphosate case. That step is welcome news to us, and we anticipate a recommendation within the next several weeks or months. Thanks to this decision, the broader timeline stays on track for a SCOTUS ruling by the summer of next year. That said, our approach has multiple fronts, and we do not hinge on any single milestone such as a favorable SCOTUS decision. As we have consistently stated, the majority of disputes like these get resolved through an agreement either inside or outside of the courtroom. Therefore, whenever it benefits the company and fits our wider strategy, we will weigh settling. To be more specific, very recently we have removed thousands of cases from the table by way of confidential settlements at a low cost-per-case average in the glyphosate litigation. On PCBs, we likewise achieved a significant settlement, on confidential terms, with the Burke case. Regarding the past Sky Valley Education Center verdicts, we are still waiting for a ruling from the Washington Supreme Court in the Erickson case. Setting aside the merits, the court processes in these Sky Valley cases have turned out to be especially difficult.
William Anderson
executiveThere's a strategy in place that limits how much we're exposed. So we are provisioning at this point for settlements that could occur. We're also staying active away from the courtroom. Legislation at both the state and federal level that reaffirms the authority of the U.S. EPA is something we welcome. Past these steps, we keep looking at further options for protecting the company, and nothing has been taken off the table. We stay acutely conscious of how this issue threatens U.S. farmers, U.S. consumers and our company. This is a significant moment, with many prongs of our strategy moving toward important junctures. Going forward, every decision we make keeps one broader goal in mind: narrowing the overall threat and moving our company nearer to containment. Let me end with a personal note. You've seen the news that the Supervisory Board agreed to extend my contract through the end of March in 2029. Their trust leaves me humbled. Leading this company — with its great mission and amazing people — for an additional 3 years is an honor for me. I know that this longer time horizon raises questions about what Bayer will look like at the end of the decade. Those questions are valid and important, and all of us take them very seriously.
William Anderson
executiveBut at this moment, you can appreciate that what we're concentrated on is the most significant task in front of the company: delivering the year, building up our pipelines, settling litigation, boosting profitability in Crop Science, and making the whole of Team Bayer leaner and quicker, with the greatest possible mission impact. I give you my word that once that work is done, we'll come out of it with a vision for how Bayer can best carry out its mission through the rest of this decade and past that point. So thank you, and Wolfgang, over to you.
Wolfgang Nickl
executiveThanks, Bill, and hello everyone from my end as well. Let me open with a bit more context around the preliminary Q2 figures we put out last week. My focus will be on the business drivers, and I'll also cover the currency impact, among other things. At the group level, Q2 net sales were up slightly, by 1%, compared with the same quarter a year earlier on a currency- and portfolio-adjusted basis. On a reported basis, we posted a 4% decline, as significant foreign exchange headwinds hit our top line to the tune of roughly EUR 550 million. EBITDA before special items reached EUR 2.1 billion, matching the prior-year quarter. Weaker earnings in Pharma were offset by improved results in Crop Science, Consumer Health and our Reconciliation. That stronger Reconciliation result came mainly from income tied to the transfer of some of our soccer players, partly offset by higher incentive provisions and balance sheet-related hyperinflation postings. The FX headwind on EBITDA before special items came to EUR 184 million in the second quarter. Core earnings per share stood at EUR 1.23, which is EUR 0.29, or 31%, higher than a year earlier, helped by a better financial result and lower taxes. The Core financial result was up by around EUR 150 million year-on-year thanks to reduced interest expenses.
Wolfgang Nickl
executiveThe core tax rate stood at just 9% during Q2, helped by a decrease in tax provisions. I'd also like to walk through the bridge from core to reported earnings per share, and that figure was minus EUR 0.20 in Q1. You can find this as well in the appendix to the presentation. The main drivers behind the delta are litigation-related expenses, which we classify as special items, partly offset by write-offs to — write-backs, sorry, to Crop Science intangibles. When it comes to glyphosate, we booked roughly EUR 1.2 billion, heavily affected by the unfavorable Anderson verdict. We'll keep appealing this case. Still, a second instance ruling results in an adjustment to our provision, as we've done previously. We also updated other litigation costs. Regarding case numbers, we settled 17,000 cases, while also accounting for new claims. On PCBs, we recorded approximately EUR 530 million as provisions and liabilities tied to the Burke case and potential future settlements connected with the Sky Valley Education Center. Here too, the provision covers other litigation costs. Given the 5-year framework of Crop Science, we additionally recorded EUR 840 million in write-backs on intangible assets in Q2 '25.
Wolfgang Nickl
executiveDuring Q2, free cash flow came in at EUR 125 million, versus EUR 1.3 billion a year earlier. That gap is mostly due to larger incentive payments, which we've factored into our full-year outlook, plus a baseline effect from the prior year tied to the timing of Crop customer payments. Year to date, free cash flow stands at minus EUR 1.4 billion — just modestly below last year, and that's even with weaker earnings and bigger incentive and restructuring payouts. Net financial debt fell by roughly EUR 1 billion from the close of Q1, landing at EUR 33.3 billion, chiefly because of FX translation effects on U.S. dollar-denominated debt. On a year-over-year basis, net financial debt dropped by around EUR 3.5 billion. Now let's dig into how the divisions performed. At Crop Science, second-quarter net sales reached EUR 4.8 billion, a 2% increase versus the prior year. The core business was up 3% year over year, with seeds and traits rising 11% in the quarter. Corn sales climbed 30% in Q2, driven by global price increases and acreage expansion. That growth was further boosted by the volume phasing we expected from Q1 after the strategic adjustment of our distribution network.
Wolfgang Nickl
executiveBecause of the U.S. dicamba label vacatur, soybean and cotton revenue fell 18% and 26%, respectively. Core Crop Protection dropped 6% during the quarter. The factors behind this were a 13% decrease in insecticides, stemming from the Movento registration expiring in the EU, along with weaker fungicides, partly offset by stronger demand for non-glyphosate herbicides. The regulatory effect tied to dicamba and Movento is still consistent with the 200 to 300 basis points impact for the full year that we communicated earlier. Glyphosate sales held steady versus the prior year, since volume bounced back from the first quarter while prices came down. Turning to profitability, EBITDA before special items reached EUR 0.7 billion, giving a margin of 14.5%. That margin expansion was driven by corn growers and significant cost savings initiatives. Let's now turn to our Pharma business. Net sales there rose 1% to EUR 4.5 billion in the second quarter. Continued growth from our launch assets kept more than offsetting the anticipated Xarelto decline. In Q2, Nubeqa and Kerendia together posted sales of EUR 729 million. Nubeqa climbed 51%, with strong growth across every region, especially in the U.S. and Europe. Although the IRA weighed on pricing in the U.S., we also saw matching positive volume momentum.
Wolfgang Nickl
executiveKerendia posted a 67% year-on-year sales gain, with the U.S. and China standing out as key drivers. Eylea held on to its number-one market position, growing 4% versus the same quarter a year earlier, and the 8-milligram dose now accounts for 25% of total Eylea sales. Our base business slipped 1% in Q2. Strong ongoing momentum in our radiology and women's health portfolio largely offset the negative volume-based procurement impact in China for Aspirin Cardio and Stivarga. Xarelto, as we had expected, was down in Q2 at 27% below the prior year. The main reasons were persistent generic competition in Europe and in Japan as well. Turning to the bottom line, EBITDA before special items fell 17% to EUR 1.1 billion in Q2, which gave us a margin of 24.5%. That margin drop stems mostly from the shifting product mix, investments in growth for launches and the pipeline, higher incentive provisions, and an FX headwind. Sales in our Consumer Health business were flat versus prior-year levels. Tough market conditions that persist in both the U.S. and China restrained growth across the portfolio. Market weakness in China weighed especially on sales in our Nutritionals business, made worse by last year's discontinuation of Care/of, our direct-to-consumer business, in the United States. We did see a 6% sales increase in Allergy & Cold, though that was against a very soft prior-year quarter, and a weaker-than-anticipated allergy season in the U.S.
Wolfgang Nickl
executiveThat held back additional expansion. As Bill mentioned earlier, we're beginning to see signs that our sharper emphasis on innovation—our power couples—is delivering results. In particular, we witnessed robust results from our Dermatology offerings such as Priorin in Germany, KangWang in China, and Actron, our Pain & Cardio product, in LATAM. Digestive Health recorded a 4% drop, coming off a strong quarter in the prior year that had benefited from supply recovery. Still, growth in MiraLAX, backed by the MiraFAST launch in the United States, partly made up for that decrease. EBITDA before special items rose to EUR 331 million, mainly fueled by efficiency gains from our new operating model and continued cost management work, even as we keep making strategic reinvestments in our brands and innovation. The margin that resulted, 23.2%, is considerably higher than last year and sits within our guidance range. Now let's turn to the divisional outlook for the full year 2025. In Crop Science, we reaffirmed our full year outlook at constant currencies, including the anticipated regulatory impacts. Given the EPA's recent proposal to approve dicamba, we're optimistic about regaining registration for the next season, which could also support soy and cotton pricing down the road.
Wolfgang Nickl
executiveOur year-to-date results have been driven by expansion in Global Corn and higher volumes in core Crop Protection. Looking ahead, we're watching for possible headwinds that may emerge after a U.S. Corn season that hit historically high levels, along with a robust rebound across other key geographies. We're also staying cautious about the dynamics in Crop Protection. For the second half of this year, we anticipate solid acreage recovery and strong market positioning in Latin America, which underpins our confidence in delivering our financial guidance for 2025. On profitability, we still expect cost savings and mix effects to secure a stable margin at constant currencies in 2025 versus '24. Given market volatility, we're sharply focused on margin resilience by executing our 5-year framework. In Pharma, we lifted our currency and portfolio-adjusted sales growth guidance on the strength of robust business performance in the first half of the year, with growth from our launch products more than offsetting declines in our maturing portfolio. Specifically for Xarelto, we now expect a sales decline towards the lower end of the EUR 1 billion to EUR 1.5 billion range previously provided. Since this pushes part of the LOE impact to 2026, we anticipate next year's sales erosion of Xarelto at a comparable level to 2025, which is, again, likely to be balanced by the continued growth dynamics of our launch products.
Wolfgang Nickl
executiveNow turning to profitability: for 2025, we're expecting the EBITDA margin before special items to land in a narrowed band of 24% to 26% at constant currencies. At Consumer Health, net sales rose 1% during the first half, with price and volume contributing evenly. We expect innovation plus the strong momentum of our power couples to speed up sales growth in the second half, though for the full year we now see growth landing at the bottom of our guidance corridor. Still, thanks to our ongoing focus on operational efficiency efforts, we anticipate the EBITDA margin before special items holding inside the range we guided previously. The final column of the chart shows our newest FX estimates, built on June month end rates for each of our 3 businesses. Sales headwinds grew larger, while the separate margin effects dropped under the materiality threshold. Taking the divisional projections together, we lifted the group's constant-currency outlook for net sales and EBITDA before special items, as Slide 12 of the presentation shows. We're likewise seeing a somewhat improved Core financial result, which we now expect to come in between minus EUR 1.7 billion and minus EUR 1.9 billion for the full year.
Wolfgang Nickl
executiveThe better EBITDA and financial results let us lift our Core earnings per share forecast by EUR 0.30 at constant currencies. Given the extra litigation-related liabilities and provisions we booked in Q2, plus how we see restructuring expenses playing out in the second half, special items for the full year are now expected to land between minus EUR 2.5 billion and minus EUR 3.5 billion. Our free cash flow and net financial debt outlook stays as previously guided, and we are confirming it. Now let's turn to how foreign exchange rates and the latest geopolitical developments are affecting us. Our FX estimate has been updated using June month end rates. With the U.S. dollar continuing to depreciate and both the Brazilian real and Chinese yuan weaker, we expect material FX headwinds on sales and earnings this year. On net debt, we anticipate a reducing FX translation effect. We're watching currency moves closely. For our business it's a big swing factor, with material impacts expected in '26 as well. Let me finish with a few comments on geopolitics and the possible direct and indirect effects on our business. On the whole, we still see high volatility. We now have more clarity on tariffs for European exports to the U.S., setting a 15% baseline ceiling without stacking for most EU exports, pharmaceutical products included.
Wolfgang Nickl
executiveWhether the sectoral probes currently underway will result in extra tariffs on pharma is still an open question. Indirect consequences are still difficult to forecast, especially regarding how consumer confidence develops and how that affects our Consumer Health business, along with the timing and execution of most favored nation principles and what they mean for truck pricing. We have to contend with a new reality of geopolitical volatility, but we have set up highly effective and flexible work streams so we can react swiftly in this new environment. We also keep working to manage our supply chains effectively, with mitigation measures covering sourcing and inventory management. In certain areas, seeds for instance, our regional footprint in production remains an advantage. For '25, given the latest status of the announcements, we still feel very well positioned to absorb potential impacts within our full-year outlook at constant currencies. As we look toward next year, we will keep carefully monitoring any potential direct and indirect developments. We work relentlessly on countermeasures to ensure stability in our supply chains and to minimize any potential effects on our business performance. Naturally, we will keep you updated as things progress. With that, I'll hand back over to you, Jost, to facilitate the Q&A.
Jost Reinhard
executiveThanks, Wolfgang, and thanks, Bill. Now we're going into the Q&A portion. Just a couple of quick housekeeping notes before we begin. <<operator_script>>. Today's first question is from James Quigley at Goldman Sachs, and after that Sachin Jain with Bank of America. James?
James Quigley
analystI have two questions, if I may. First, on the Pharma upgrade. When you look at Xarelto versus the rest of the business — your initial expectation for Xarelto was a reduction of EUR 1 billion to EUR 1.5 billion because of generics. And now, perhaps at the lower end of that, the guidance suggests roughly EUR 725 million in revenue uplift. So should we think of about 1/3 of that as Xarelto and maybe 2/3 as the other products? And connected to that, you mentioned Nubeqa and Kerendia could reach EUR 2.5 billion. We are currently annualizing at EUR 2.8 billion. So how much upside to that is embedded in your guidance? Or might there be further upside from stronger performance there? Second, on the glyphosate litigation. You recently settled an additional 17,000 cases at a low cost per case. How significant is this as a turning point, or turning the corner, for glyphosate litigation? Could you also address the quality of those cases? In the past, you have spoken about some non-blood cancer cases in the inventory. So is this simply a cleanup of lower-quality cases? Might it represent a capitulation by some of the plaintiff lawyers, or could there potentially be some read-across here to other cases within the inventory?
Wolfgang Nickl
executiveThanks, James, for that question. Regarding Xarelto, you're correct. We've provided a bit more precision in our guidance. We will now land at the lower end of the EUR 1 billion to EUR 1.5 billion decline for Xarelto. And we figured this was a good moment to do that, especially since we've just had further court proceedings that have validated our patent in Germany. So most likely we won't be able to maintain our preliminary injunction there, even though we will appeal it. And at a later stage, hopefully, we can get that ruling reversed. So at this point we have a fairly solid picture of where we'll end up this year in Europe with Xarelto, and that is reflected in the figures we've provided. But you're right. I mean, when you look at the favorable Pharma business, a large portion of this comes from how our launch brands are performing, and we're especially pleased with what we're seeing from Nubeqa and from Kerendia. You're right, we have guided more than EUR 2.5 billion in total sales for this year. We're going to exceed that, but that's also the reason we guided more than EUR 2.5 billion.
Wolfgang Nickl
executiveAs I recall, the consensus at present is roughly EUR 2.9 billion. Our teams are therefore pushing hard to reach that level and exceed it. That is everything I can share at this point. I would rather not give greater precision, since we are rolling out several new indications. These include ARANOTE for Nubeqa as well as heart failure for Kerendia. So at the moment there is a degree of uncertainty regarding how this will influence uptake going forward, though on balance it ought to be good news.
William Anderson
executiveOkay, and James, turning to the glyphosate settlements — you were right when you noted that we resolved 17,000 cases at a low cost per case. Still, we don't really make comments on matters such as quality, and I'd rather not get into whether this represents a turning point. What I would say is this: yes, we are turning over every stone to make sure we're executing on all the various approaches we've called out in the past, and we remain committed to substantially containing this litigation threat to the company by the end of next year. Beyond that, there isn't much more I can say.
Jost Reinhard
executiveSachin is up next.
Sachin Jain
analystLet me try two more questions on litigation, plus one for Wolfgang on free cash flow. You've been sounding more and more committed to resolving these cases by the close of '26. How should we think about what it costs to settle and finish this matter, measured against the existing provision's size? And I'm curious how SCOTUS alters that calculation. Our assumption is that SCOTUS would matter in that context, so why pursue the initial settlement ahead of SCOTUS? Second, a similar question on PCB. I'm simply trying to understand how this initial settlement cuts the exposure at Sky Valley compared with the Washington appeal still underway on Erickson. Also, any detail on how large you see a personal injury complex beyond Sky Valley? And if I can, one for Wolfgang: since litigation clearly dominates the discussion, how should we view the free cash flow outlook over the midterm if you keep settling more and cash outflows show up against your balance sheet structure?
William Anderson
executiveAbsolutely. Yes, I can simply state that we are engaged across all of the different fronts, from legislative efforts to court appeals at multiple levels, including the Supreme Court, and we are in conversations with policymakers. I mean, this is a significant matter that impacts American farmers, American consumers, and American food security, and many people are paying attention to it. And I can simply say that we want to get this resolved. And we are not certain which mix of factors will be involved, and what the precise cost of resolving it will be — those are things that hinge on a number of factors. But we believe we have put mechanisms in place that will let us maintain our commitments on it. With respect to PCBs, I would simply say that the situation in Washington State and this particular litigation concerning the Sky Valley Education Center — we have run into some processes and procedural matters that are highly specific and local that are especially difficult, and we have made some decisions about, yes, working to resolve some of this and this litigation. And so it is part of the overall picture. And I can assure you, we are asking all the right questions regarding how this relates to other potential personal injury cases outside of the Sky Valley complex.
William Anderson
executiveNot a lot has happened on that front. Ultimately, a big part of this comes down to the fact that, sure, the evidence of exposure is quite minimal. And sure, we think our overall position is solid, but we keep working every angle. And Wolfgang, perhaps you'd like to discuss the cash flow?
Wolfgang Nickl
executiveSure, happy to. Sachin, yes — first, regarding cash flow for this year: even with the high provision, we're maintaining our free cash flow guidance range of 1.5 to 2.5 for the year. The reason is simply that a number of those provisions don't even have an underlying agreement behind them. Take Anderson, for example — technically we have to reserve for that as we move into appeals on it. So it doesn't result in cash going out. And where an agreement does exist, we obviously try to phase that into the future. That's why we'd keep the free cash flow. Our prime focus is maximizing free cash flow outside of litigation. And wherever we reach solutions, we're trying to face it wherever we can. I can't say today how that will impact '26, '27, '28. But rest assured, we're trying to face it, and we'll tailor our other financials accordingly.
Jost Reinhard
executiveThanks. We still have additional questions lined up. Up first is Richard Vosser with JPMorgan, followed by Matthew Weston of UBS. Richard, the floor is yours.
Richard Vosser
analystAppreciate it, Jost. I've got a couple of questions, if I may. First, could Stefan update us on how the acoramidis launch is progressing in Europe — both within Germany and outside it, and what you're expecting there? Second, regarding Crop, looking ahead to the second half: you mentioned a strong season in LatAm, but I was hoping for more detail on both corn and soy, and on how we should think about the price and volume components as we move into that period?
Stefan Oelrich
executiveRichard, appreciate the question. We're quite happy with how it's being taken up. So we've launched so far in Germany and Denmark, and we're preparing to roll out in additional countries. What we're observing is extremely favorable acceptance of the reimbursement dose we have here. So with this product, we ought to actually be surpassing the typical timeline for reaching the market in Europe, which I believe speaks to the efficacy that prescribing physicians as well as payers throughout Europe are seeing. And thus far, we're off to a really, really strong beginning in our first quarter on the market, with uptake that is probably also greater than anticipated, very robust new-to-brand share in Germany, which positively caught us somewhat off guard, but it's early days. So I don't want to treat those 2 months as a signal of what's still ahead, but it's a strong start.
Rodrigo Santos
executiveAnd Richard, let me take the Crop Science question. So yes, we feel good about the second half, given some of the factors you brought up. And to give a bit of context from '24, last year we saw a big cut in Corn acreage in key markets such as Mexico and Argentina as well. So part of that market recovering will benefit this season in Corn. So we still see a strong season for Corn worldwide. We saw that in the first 6 months of the year with the 7% growth we had, but we see it in the second half too. But also in Soybean, as you said, Soybean, we're excited that our second generation of Intacta, Intacta 2 Xtend in Brazil will likely reach more than 20% penetration this year, well ahead of any projection we had before in terms of how fast we're moving. Of course, Intacta makes up the majority of the market, but we're seeing our second generation grow with the new varieties we're bringing to market.
Rodrigo Santos
executiveCombining those pieces — for corn and soybean, along with the cost-saving steps we're implementing and the operational measures we're putting in place — that's what gives us confidence for the second half of the year, together with how we performed during the first 6 months, and that is why we are reaffirming our guidance here today. So we remain on track for '25. And at the same time, there's a lot of execution happening on the 5-year framework, as both Bill and Wolfgang mentioned. Thanks for your question, Richard.
Jost Reinhard
executiveMoving on, our next question comes from Matthew Weston at UBS. Matthew?
Matthew Weston
analystThree questions, if I may, with a little one at the end as a cheat. First, on the dicamba reregistration and how it might affect 2026: I'd like to know whether you believe the registration timeline is such that it could have a full impact in '26. So do we think it might start more beyond that? And also, do you think the market is positioned so that customers could gain leverage to push price higher as you add the trait back? Or has the market moved on, making that very challenging? Second, on asundexian: obviously there's heightened investor attention on OCEANIC-STROKE, with primary completion on clinicaltrials.gov listed as October of this year. Is the event rate tracking as expected? And is that October timeline still a reasonable assumption? And the final, third one, if I can cheat quickly: we had phasing impacts in crop during the first half because of your distribution change. Should we expect any phasing impacts in the second half?
William Anderson
executiveRodrigo, how about you handle the first question and the third one, and then Stefan can cover asundexian.
Rodrigo Santos
executiveI'll take that. Matthew, regarding the third question, that one's straightforward. We saw some phasing of the go-to-market adjustment in North America move from Q1 into Q2, and for the second half of the year we don't anticipate any changes to that. So that one's easy. On the first one, about dicamba, we're collaborating very closely with EPA and the process. So we're confident we'll have the label for the '26 season. It's still early to discuss the full impacts of the '26 season on our business, because as you know, we're working on that in Q3. What I'd say is that today's projections from a market standpoint — since we're going to have a full season of Corn, and we had 95 million acres of Corn in the U.S. this year — you can see that reflected in the future price of Corn; so you'll probably see a somewhat more favorable market for Soybean next year versus Corn. And we see some opportunities with Soybean thanks to the label, but also with the business we have. So yes, we potentially see more benefits for Soybean next year, but it's still early to be precise on that one, and we'll come back to you on that in Q3.
Rodrigo Santos
executiveThanks. Over to you, Stefan.
Stefan Oelrich
executiveMatthew, I appreciate the question about asundexian, and I passed that along to you. My enthusiasm keeps building as we get closer to the readout from the OCEANIC-STROKE trial. Regrettably, there isn't anything genuinely new for me to share. We've consistently stated that we anticipate the readout during the fourth quarter. That aligns precisely with what you just cited. So there's no additional update from me. Let's wait and see. There are no negatives and no positives — which perhaps is itself a positive.
William Anderson
executiveYes. And Matthew, did I hear him correctly — he mentioned October?
Stefan Oelrich
executiveRight, so we're talking about the fourth quarter.
William Anderson
executiveYes. And I’d really point to the fourth quarter. So I don’t want anyone feeling let down if by Halloween there isn’t an asundexian stroke result, because, I mean, it is Q4, but that doesn’t mean it has to be October.
Jost Reinhard
executiveTherefore, the next two questioners are Emily Field from Barclays and then Vincent Andrews from Morgan Stanley. Emily, go right ahead.
Emily Field
analystSo this is sort of one big question with multiple parts, about evolving policy and a possible launch. Bill, I suppose whether you're lucky or unlucky depends on how you look at it, but you weren't among the people who received one of those letters from President Trump last week about what the administration wants from the industry on pharma pricing. So I wanted to ask whether you have any thoughts on MFN and how it might affect — how it would impact your business in the U.S. And part of that letter talked about new launches. With elinzanetant, you may be close to launching a new medicine here in the United States. Does that play into how you're thinking about pricing? And the final piece is just how confident you are that you can secure a label for that medication without a box warning.
Stefan Oelrich
executiveWould you like me to handle that? I'll handle it, and I'm happy to pass it over to you.
William Anderson
executiveLet me begin, and then you can pick up — so indeed, no letter arrived, though clearly the U.S. represents a hugely important market for us. As I believe we've said in the past, from a value perspective we are a net exporter of pharmaceutical products from the U.S. out to the world. And we hold a great deal at stake in maintaining global supply chains and free trade. So our genuine hope is that policymakers in the U.S. as well as in other countries can reach agreements permitting free trade to continue, since yes, I'd say the world has a great deal riding on this. When it comes to the '25 impact — we've discussed that. I think we've mostly offset it. But as time goes on, it's — yes, figuring out a better solution than certainly than high tariffs is going to serve the best interests of the people of America and other nations. And perhaps, Stefan, you'd like to speak about elinzanetant and tell us where things stand there?
Stefan Oelrich
executiveEmily, obviously the fact that no letter arrived doesn't stop us from taking a thorough look at the situation and getting ready for what could follow. We get that the U.S. administration is taking a close look at how other countries set prices. And I think that's their perfect right to do so. At the same time, let's not forget the investments that we and other companies are bringing to a very innovative landscape in the U.S., which in itself creates tremendous value to U.S. citizens, the economy and last, but not least, of course, also patients. But what does that mean for us? So when we price, generally, we look at global pricing and potential interdependencies and now maybe even a little bit more so, that includes, obviously, Lynkuet as we await approval by the FDA. And I've been on record saying that this is also a clear shout-out when it comes to innovation and new launches to European payers and European governments that we need stronger support to innovation like we've seen it in the U.S. over a long period of time when it comes to newly introduced medicines into Europe and other geographies. And I think we will make that point even more significantly going forward.
William Anderson
executiveRegarding Label, she raised a question as to whether black box...
Stefan Oelrich
executiveSo, regarding Lynkuet and the label—that's what we're discussing right now at this point. You've heard me express cautious optimism about the Lynkuet label here in the U.S. In the U.K. and Canada, the label action has been very positive. And I'm pleased to say that Swissmedic approved Lynkuet in Switzerland last night as well. From the FDA, we have no indication that there's any reason the product shouldn't be approved. There have, however, been discussions regarding additional data. So we've agreed to a 90-day extension of the PDUFA date. And I believe our data is strong. When you look at the labels in the U.K., in Canada, and now in Switzerland, it's clear we have a very strong product—a differentiated one—differentiated because our mechanism of action is different, and we have very strong data supporting that.
Jost Reinhard
executiveGreat — Vincent, you’re up next.
Vincent Andrews
analystRodrigo, I was hoping you could share a bit about what seed production costs look like. How far have they fallen this year? And what's your expectation for the decline next year, in the Northern Hemisphere as well as the Southern Hemisphere?
Rodrigo Santos
executiveThanks, Vincent. Yes. And one thing worth adding is that with the season we're having — high yields for the farmers, high yields for us too — it's a great season on seed production, and that brings our cost down. But we're also taking plenty of measures across all the different business lines we have. On Soybean, there are mainly items we're doing to cut cost, and on Corn as well. And of course, you know the CP story very well. We're going to keep doing those things for '26 and beyond, because our 5-year framework includes that. On our EUR 1 billion margin expansion, or cost saving, Vincent, EUR 600 million of that comes from product supply across different areas where we're applying it. Again, a big portion of that is on CP, but we also have a portion of it on Seeds & Traits. So we delivered EUR 500 million of savings with the operating model in product supply this season, and we'll keep working that with the same discipline in the years ahead as well.
Rodrigo Santos
executiveYet it's a key part of the plan we have for the coming 5 years. Thanks, Vincent.
Vincent Andrews
analystAnd to follow up on Crop Protection, could you discuss what the pricing outlook looks like, both for your traditional products and for what you're seeing in the glyphosate arena?
Rodrigo Santos
executiveYes. Regarding the core CP, Vincent, we remain cautiously positioned on that front, since pricing dynamics in the market continue to be highly competitive with generics, particularly in regions such as Latin America. So, in the second half of the year — for example, in Latin America, which is a key market — pricing pressure is going to persist. That's what we're assuming here. We do have new launches. We have new <<inaudible>> that we're bringing to market in Latin America. We have Fox Xpro expansion, and we have <<inaudible>> expansion, which will support our plans for the second half. I had the chance to read the report you guys published on the chemistry. And hopefully, next season, we'll see a better market for that one, but we're still expecting highly competitive pricing in the core business during the second half of the year. And the same holds for glyphosate. With glyphosate, dynamics differ in North America owing to the tariffs. Pricing there is better. But again, in Latin America, competition from generics in glyphosate is very intense as well. So we're assuming that pricing will be highly competitive in the second half of the year.
Rodrigo Santos
executiveWhat we've come up with and the rollout ought to support what we're aiming to do in the back half.
Jost Reinhard
executiveGreat. Queued up next we have Christian Faitz with Kepler Cheuvreux, then Rajesh Kumar from HSBC, and finally Laurent Favre of BNP Paribas. Christian, you're up next.
Christian Faitz
analystYes. Congratulations on the results and the litigation progress. Two questions, please. When do you expect the currently sluggish market environment for Consumer Health products to improve? Would it be fair to assume that '25 is kind of a loss year in this respect, and also with the main Allergy season having passed? Second question, I'm aware that the Movento registration expiration in Europe might have been the main reason for the minus 4% organic shrinkage in the region yet. Could you also share your thoughts on a possible inventory buildup in Europe on the back of adverse weather? I know that fungicides were also down and not only insecticides, so hence the question.
Wolfgang Nickl
executiveYes. So Christian, thank you so much for the question. I actually — even though the market is not as strong as we were predicting for the whole of 2025, I wouldn't actually call it a loss year. I think there are many things that are taking place in the market. You have a market that is now more balanced between price and volume. We, ourselves, for example, our volumes have been developing extremely well. We usually track the evolution index of how do we do against our competitors, be it multinational companies or local competitors. And we're actually pleased with what we're seeing in terms of this volume and price dynamics. So I wouldn't call it and I wouldn't go as far as calling it a loss year. It's been softer than we were expecting. A lot of it is driven by the U.S., the consumer sentiment in the U.S. has impacted us and all of the industry. But not only the U.S., China also has been pretty soft. You're right. We expect that to continue for the rest of the year 2025. And hopefully, in 2026, we see a pickup of the market, maybe not to the levels that we were expecting for this year, but we see a pickup.
Wolfgang Nickl
executiveSo that's really a question about 2025. You're also correct that this year's allergy season, particularly up in the Northern Hemisphere, didn't turn out as strong as we had anticipated. Typically, if you look at the allergy curves, there is a bit of an uptick late in the year — believe it or not — in the Northern Hemisphere. And with luck, the Southern Hemisphere will give us a stronger allergy season. That's essentially what we expect to unfold over the remainder of the year, so that we can reach the low end of our sales guidance. Thanks for the question.
Rodrigo Santos
executiveOkay, Christian, let me take on your Crop Protection question. You're right about that. So here's a figure I believe ties directly to what you asked. In the first 6 months of the year, Crop Protection came in at minus 2%. Strip out the regulatory effect from Movento, and we'd be sitting at plus 1%. That means our core Crop Protection business would have grown during the first 6 months of the year. So the regulatory impact really is the story, as Wolfgang mentioned earlier in his remarks. And it's mostly a volume effect rather than pricing, which connects to what Vincent asked about. In the second half of the year, we're seeing more innovation. We're focused on the Plenexos launch, an insecticide that will reach 70 countries and 50 crops. We're talking about the icafolin registration. So innovation in Crop Protection is going to be a major element over the coming years, as we set out in the plan, and we'll keep at it. As for that specific market you brought up, there are always some weather events, and as you said, they can affect fungicide use.
Rodrigo Santos
executiveWhen it comes to Europe, though, we're watching channel inventory very closely, and we review it each month. So as of today, we aren't seeing any major issue. Naturally, during the summer, we'll need to keep an eye on the weather and how the market is affected, but we're tracking that very closely, and up to now we don't foresee a major challenge on that front. Thank you.
Jost Reinhard
executiveRajesh, you're up next.
Rajesh Kumar
analystI apologize. Two things, if I may. First, going back to what Sachin asked regarding the future of free cash flow — and I understand you can't provide guidance on free cash flow for '27, '28, or '29; that would be ridiculous — but when we think about the cash conversion algorithm, obviously you're building out all these provisions, and there will be some future cash flow tracks. So structurally, looking at your cash conversion over the next 3 years, should we expect lower cash conversion than historically seen for the business models? And the second question is just a clarification. In the release, I noticed — and this is in an adjusted number — in the release, I noticed there was an impairment loss reversal in the Crop Science division. I know this isn't flattering your adjusted numbers or numbers before one-offs. But I'm just curious, what drove that reversal? Because that means something is worth better than what you initially thought.
Wolfgang Nickl
executiveYes, Rajesh, happy to. We'll provide some indication. I think you understand that I also won't be giving guidance for '26 at this point. That said, I would note this. First, we've consistently stated that we will deliver on '25, and we're working on a '26 that's heading in the opposite direction. So profitability is obviously where it all begins. And as I mentioned in my remarks, we're watching the operational side in particular, but we also have to keep an eye on FX there. I'm actually fairly pleased on the operational side with what we call cash conversion. On the cash conversion cycle, given the progress we're making on inventory, along with the progress on AP and AR, that's trending the right way. So that part is within our control. We're focusing relentlessly on it, by the way, and on CapEx efficiency too. So that covers the operational side. I can't tell you today how potential settlements we haven't completed yet will affect that cash flow. That's why, internally, we'll focus entirely on the operational piece. And then, as I said when responding to Sachin's question, we try to be very thoughtful in how we structure potential payouts so they fit into this picture.
Wolfgang Nickl
executiveOn the impairment question, Rajesh, here's how it works. Normally, unless a triggering event occurs, we review our intangible assets as a matter of routine each Q4. In May, my colleague Rodrigo gave a presentation on a 5-year plan, and that counted as such a triggering event. It produces effects of various kinds. I'd put it at three or two. Our Corn business appeared somewhat stronger in the outward years, which is a positive. That means write-backs on the cash-generating units became possible. Then there are plenty of technical consequences, such as the further writedown of the vegetables a bit that you saw, which stemmed purely from a rise in the weighted average cost of capital — purely technical. On balance, the result was EUR 840 million positive, with no impact on the goodwill. So that left us happy. I hope that answers your question.
Jost Reinhard
executiveAnd the final person in the queue is Laurent Favre.
Laurent Favre
analystI have two questions, if I may. The first is directed at Stefan. Stefan, I believe Wolfgang said you anticipate that Xarelto's sales will fall next year by an amount comparable to this year. So I wanted to ask whether that remark refers to the absolute drop — meaning at least EUR 1 billion — or whether it is really about the percentage decline versus the prior year. That is my first question. Then the second one is, I believe, for Bill. You said it is too early to discuss what Bayer might look like in 2029, and I take it you mean the conglomerate structure. But perhaps mine is a somewhat different angle. Do you expect Bayer to still be the owner of the Leverkusen Football Club? And is that question completely off-limits when it comes to what I assume is a very noncore asset?
Stefan Oelrich
executiveAlright, let me begin. It's a bit soon to say much about next year, though we have stated that Xarelto should come in at roughly EUR 1 billion. So we'll head toward that landing, apart from the U.S., where exclusivity remains in place until early '27. But we are getting close to that landing zone, so to speak, by late '26. I believe that ought to give you some direction.
William Anderson
executiveOkay, and Laurent, yes, I’ll address your question. I just want to say — going back to what Rajesh raised regarding free cash flow and our capacity to produce cash — I want to state, for the entire Board, that we are extremely focused on this matter, since I believe all of us felt that when we began this effort a couple of years back, cash generation was wholly insufficient. That is precisely why we have a huge push underway here. People in the businesses have incentives tied to cash flow. A substantial portion of our incentive relates to cash flow. And we look forward to improved cash flow days, especially cash flow from operations, as we intend to keep expanding Consumer Health through this rather difficult period; Crop Science this year posed a specific challenge owing to those regulatory events. Yet, as we have stated, we intend to grow it consistently year-over-year and bring Pharma back to growth in 2027. So we anticipate many robust years of cash flow. And — regarding your question about the football club, first, let me address the football club: over the last — a bit more than 2 years since I joined the management board, I think we have devoted a total of roughly 5 minutes, perhaps, to discussing the football club.
William Anderson
executiveNo — the football club is a wonderful legacy of Bayer, since for those who aren't aware, the reason we ended up with a football club is that we had 70,000 employees in Leverkusen, and many of them were actually very good football players. So we had an amateur club. And that — and when the German professional clubs got going in earnest, our amateur club was competitive. So it became a professional club, and it is to this day, and I would say we're very proud for the club, but we don't spend any time managing the club. But we're very proud that last year, they won the Bundesliga with a payroll, about 1/3 of the payroll of the best funded team. But we — yes, that being said, as far as we can see, the club will remain a part of Bayer because for a simple reason, from a legal standpoint, there actually is no way to sell it. And so it's a permanent fixture as it were because of the rules of the Bundesliga about ownership. We have an exception there because of the historical reason we came to have a football club.
William Anderson
executiveBut it's not going anywhere. We're big fans of it. Wherever we travel globally, the club is recognized. During my time in China — that was the year before last — I happened to be there on the day we clinched the Bundesliga Championship, and every one of the senior party officials offered their congratulations, since they all follow the Bundesliga — I believe the matches air on Sunday afternoons for them. So that's a long reply to a brief question, but Bayer 04 isn't going anywhere.
Jost Reinhard
executiveOkay, so we’re only a few weeks out from when the season begins. That’s all the time we have for today’s call. We really appreciate your questions and your interest. And I hope everyone has a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.